---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030624"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T01:50:55.042889+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix reports positive UroShield study; 1/3 of patients saw fewer blockages

## Summary
- Approximately one-third of patients reported reduction in catheter blockages and need for unscheduled changes.
- Qualitative data showed favorable opinions from majority of participants in the independent study.
- Study published on ScienceDirect; investigated UroShield's effect on CAUTI and catheter blockage.
- CEO highlights market opportunities and need for alternatives to antibiotics in long-term catheter care.

## SEC filing metadata
- accession: 0001493152-23-030624
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315223030624/0001493152-23-030624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315223030624/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030624
- JSON: https://secwatch.observer/filing/0001493152-23-030624.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.